Quantitative analysis of irbesartan in commercial dosage forms by kinetic spectrophotometry

Chemical and Pharmaceutical Bulletin

Volumn 54, Issue 5, 2006, Pages 626-631

  Rahman, Nafisur ^a   Siddiqui, Masoom Raza ^a   Azmi, Syed Najmul Hejaz ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Commercial dosage form; Irbesartan; Kinetic; Spectrophotometry; Validation

Indexed keywords

IRBESARTAN;

ARTICLE; DRUG FORMULATION; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS; SPECTROPHOTOMETRY;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; COLOR; EXCIPIENTS; INDICATORS AND REAGENTS; IODATES; KINETICS; POTASSIUM COMPOUNDS; POTASSIUM IODIDE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS; TEMPERATURE; TETRAZOLES;

EID: 33646396482     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.54.626     Document Type: Article

References (17)

1. Markham A., Spencer C. M., Jarvis B., Drugs, 59, 1187-1206 (2000).
2. "Martindale the Extra Pharmacopoeia," 33rd ed., Royal Pharmaceutical Society, London, 2002, p. 914.
3. Sane R. T., Francis M., Pawar S., Indian Drugs, 39, 32-35 (2002).
4. Erk N., J. Chromatogr. B, 784, 195-201 (2003).
5. Chang S. Y., Whigan D. B., Vachharajani N. N., Patel R., J. Chromatogr. B, 702, 149-155 (1997).
6. Li J., Wu Q., Wang L., Yaowu Fenxi Zazhi, 21, 249-250 (2001).
7. Hillaert S., Vanden-Bossche W., J. Chromatogr. A, 979, 323-333 (2002).
8. Hillaert S., Vanden-Bossche W., J. Pharm. Biomed. Anal., 31, 329-339 (2003).
9. Isabel I., Rodenas V., Garcia S., Sanchez-Pedreno C., J. Pharm. Biomed. Anal., 29, 299-305 (2002).
10. Erk N., Pharmazie, 58, 543-548 (2003).
11. Perez-Bendito D., Gomez-Hens A., Silva M., J. Pharm. Biomed. Anal., 14, 917-930 (1996).
12. Sierra-Jimenez F., Sanchez-Pedreno C., Anales real Soc. Espan. Fis. y quim., 54 B, 541-552 (1958).
13. International conference on Harmonisation, ICH Harmonised Tripartite Guideline-Text on Validation of Analytical Procedures, Fed. Regist., 60, 11260 (1995).
14. Hartmann C., Smeyers-Verbeke J., Penninckx W., Heyden Y. V., Vankeerberghen P., Massart D. L., Anal. Chem., 67, 4491-4499 (1995).
15. Canada Health Protection Branch, Drugs Directorate guidelines, Acceptable methods, Ministry of National Health and Welfare, Draft, 1992.
16. Chando T. J., Everett D. W., Kahle A. D., Starrett A. M., Vachharajani N., Shyu W. C., Kriplani K. J., Barbhaiya R. H., Drug Metab. Dispos., 26, 408-417 (1998).
17. Miller J. N., Analyst, 116, 3-14 (1991).